구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | ATLCAR.CD30 cells |
Overview Company | National Heart, Lung, and Blood Institute (NHLBI) |
Overview Modality | CGT |
Overview Target | CD30 |
Overview Indication | Lymphoma; Lymphoma, Non-Hodgkin |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K/BRD4 inhibitors.. The inhibition of PI3K has only a limited therapeutic effect and often leads to drug resistance. Combining PI3K and BRD4 inhibition results in a beneficial antitumor effect in MYC-driven hematological malignancies and solid tumors, underlying the significance of develop… |
Clinical Safety signal | Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K/BRD4 inhibitors.. The inhibition of PI3K has only a limited therapeutic effect and often leads to drug resistance. Combining PI3K and BRD4 inhibition results in a beneficial antitumor effect in MYC-driven hematological malignancies and solid tumors, underlying the significance of develop… |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | ATLCAR.CD30 cells |
Overview Company | National Heart, Lung, and Blood Institute (NHLBI) |
Overview Modality | CGT |
Overview Target | CD30 |
Overview Indication | Lymphoma; Lymphoma, Non-Hodgkin |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Toxicology Major finding | Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K/BRD4 inhibitors.. The inhibition of PI3K has only a limited therapeutic effect and often leads to drug resistance. Combining PI3K and BRD4 inhibition results in a beneficial antitumor effect in MYC-driven hematological malignancies and solid tumors, underlying the significance of develop… |
Clinical Safety signal | Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K/BRD4 inhibitors.. The inhibition of PI3K has only a limited therapeutic effect and often leads to drug resistance. Combining PI3K and BRD4 inhibition results in a beneficial antitumor effect in MYC-driven hematological malignancies and solid tumors, underlying the significance of develop… |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교